Current Japanese Breast Cancer Society Clinical Practice guidelines recommend a CDK4/6 inhibitor plus an aromatase inhibitor as a first-line endocrine therapy for postmenopausal patients with HR+/HER2‒ ABC [12]. Here, HR is linked to breast cancer.